The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Risk factors associated with high-risk patients with PV: An update from IACH 2024
|
During the 7th Annual Meeting of the IACH, Alvarez-Larrán discussed factors that should be considered in the risk stratification of patients with PV.1 Risk factors associated with the complications of high-risk PV, such as arterial/venous thrombosis, increased bleeding, and disease progression, were also discussed.1 |
| Key learnings |
| High-risk patients with PV are stratified based on age >60 years, a history of arterial/venous thrombosis, persistent leukocytosis, and inadequate hematocrit control with phlebotomies. |
| Risk factors associated with arterial thrombosis include the history of arterial thrombosis, age >60 years, cardiovascular risk factors, and TET2/DNMT3A mutations. Risk factors related to venous thrombosis include JAK2V617F VAF >50% and an NLR >5. |
| Extreme thrombocytosis and AVWD (VMF <30%) are associated with increased bleeding. |
| JAK2V617F VAF >50%, TP53 mutations, and chromatin/spliceosome mutations have been linked with disease progression to MF or AML. |
| A personalized approach that considers individual risk factors may be needed in the stratification and management of patients with high-risk PV. |
Abbreviations: AML, acute myeloid leukemia; AVWD, acquired von Willebrand disease; IACH, International Academy for Clinical Hematology; MF, myelofibrosis; VAF, variant allele frequency; VMF, von Willebrand factor; WBC, white blood cell.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
